EL7.AI
StocksMedium•29 July 2026•
1 min read

Teva Raises 2026 Outlook Following Record UZEDY Sales Growth

Key Facts

1UZEDY net sales for schizophrenia treatment reached a record $77 million in Q2 2026, up 43% year-on-year.
2Teva raised its 2026 UZEDY revenue outlook to a range of $270 million–$290 million.

In a move reflecting its successful pivot toward specialized pharmaceutical growth, Teva Pharmaceuticals reported strong quarterly results driven by the record performance of UZEDY. According to reports, net sales for the schizophrenia treatment reached $77 million in Q2 2026, marking a 43% year-on-year increase. The drug is currently positioned as the fastest-growing long-acting injectable treatment in the U.S. market.

Following this momentum, Teva has raised its 2026 revenue outlook for UZEDY to a range of $270 million to $290 million. This upward revision highlights continued growth in key product lines, benefiting both Teva and its partner Medincell. The guidance update underscores management's confidence in the product's ability to capture further market share throughout the remainder of the fiscal year.

Market data shows TEVA shares closed at $31.67 as of July 28, 2026, after trading between a session low of $31.02 and a high of $31.88. Investors should monitor broader market sentiment following upcoming economic catalysts, including German Consumer Confidence and UK Retail Sales data scheduled for release on July 24.